Updates on the work of Manitoba’s Enhanced Therapy Institute
Here at Manitoba’s Enhanced Therapy Institute, we have been busy paving the way for MDMA-Assisted Therapy in this province. Here’s a brief overview of what we have been up to.
New York Times agrees with my opinion on why FDA delayed approval of MDMA Assisted Therapy
In recent article, New York Times seems to paint a picture that closely resembles my own understanding of why FDA Assisted Therapy was delayed by the FDA.
“Why did FDA delay the approval of MDMA Therapy?” with Rick Doblin – MDMA THERAPY PODCAST #24
Rick Doblin, legendary founder of MAPS, discusses his views on the recent unexpected decision by the FDA to delay the approval of MDMA-Assisted Therapy for broad clinical use. In this interview, Rick clarifies each point raised against MDMA therapy in the recent controversy, then counters and dispels most of the criticism that was raised against the studies.
Nothing Has Changed About the Healing Power of MDMA-Assisted Therapy
So after years of hype and hope, the FDA did not approve MDMA Assisted Therapy for the treatment of PTSD at this time. This is a tectonic shift in the entire field of psychedelic therapies. Here are some of my reflections on this historic decision.
“How MDMA Therapy saved a veteran” with Jonathan Lubecky – MDMA THERAPY PODCAST #23
After several suicide attempts, a US veteran found MDMA Assisted Therapy, which he claims not only saved his life but also cured him of PTSD. Listen to Jonathan’s remarkable story.
How Power Trip became its own power trip
A report on the state of the MDMA Therapy orchard
“What happened at the FDA Expert Panel meeting regarding MDMA Therapy?” with Matthew Baggott – MDMA THERAPY PODCAST #22
Dr. Matthew Baggot (a neuroscientist and expert on both the neurophysiology and phenomenology of MDMA and on the FDA drug approval process) shares a number of very interesting, unique, and nuanced insights about the FDA Expert Panel meeting regarding MDMA-Assisted Therapy.
FDA Psychopharmacologic Drug Advisory Committee rejects use of MDMA-Assisted Therapy for PTSD
In a stunning decision, an FDA-appointed advisory committee, comprised of 11 independent experts, rejected MDMA-Assisted Therapy as a treatment for PTSD, voting that the evidence for both its effectiveness and safety is insufficient.
Psychedelic Alpha on June 4th FDA Advisory Meeting
June 4th is fast approaching, with a group of experts scheduled to meet to advise the FDA on whether to approve MDMA-assisted therapy for the treatment of PTSD.
June 4 2024 is an important date for MDMA-Assisted Therapy
The FDA is currently in the final stages of the MDMA-Assisted Therapy approval process, with the decision expected in August 2024. The next stage in the approval process is the meeting of the FDA Advisory Committee on June 4 to review Lykos Therapeutics’ application.
